Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Hogan Lovells hires pair of patent litigators
Biotech
Both attorneys have ‘exceptional experience’ in life sciences and previously practised at Dechert.   5 October 2023
J&J pledges not to enforce TB patents in certain countries
Africa
Non-profit hails move but urges other big pharma companies to follow suit | To avoid litigation, manufacturers must ensure generic versions are of good quality, medically acceptable, and are used only in the selected low-and middle-income countries.   3 October 2023
‘A huge shame’: UPC denies access to pleadings and evidence in Sanofi v Amgen
Pharma
An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.   26 September 2023
Americas
Long-running legal dispute tackles questions of enablement and ‘undue experimentation’ | Federal Circuit says it is bound by SCOTUS’ findings in Amgen v Sanofi.   21 September 2023
Pharma
Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month.   19 September 2023
Pharma
Healthcare company accuses online sellers of selling unauthorised over-the-counter products | Consumers leave bad reviews after receiving damaged, expired and poor quality goods, says the complaint | Vory, Sater, Seymour and Pease.   5 September 2023
MedTech
Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.   10 August 2023
Biotech
Swedish company’s products treat urologic disorders and colorectal conditions | Portfolio includes unique treatment for prostate cancer radiation therapy.   27 July 2023
Americas
Precedential decision marks blow for medical device maker after earlier win | PTAB criticised for “fundamental legal error” and “narrow definition”.   11 July 2023
Generics
Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.   11 July 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.